Last $0.14 USD
Change Today +0.002 / 1.43%
Volume 124.7K
SCRC On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

scripsamerica inc (SCRC) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/16/13 - $0.65
52 Week Low
10/11/13 - $0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SCRIPSAMERICA INC (SCRC)

Related News

No related news articles were found.

scripsamerica inc (SCRC) Related Businessweek News

No Related Businessweek News Found

scripsamerica inc (SCRC) Details

ScripsAmerica, Inc. primarily develops, markets, and distributes branded over the counter (OTC) pharmaceutical products in the United States and China. It primarily focuses on the marketing, sale, and distribution of RapiMed pediatric acetaminophen products. The company was founded in 2008 and is based in Tysons Corner, Virginia.

2 Employees
Last Reported Date: 04/22/14
Founded in 2008

scripsamerica inc (SCRC) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $120.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $178.0K
Compensation as of Fiscal Year 2013.

scripsamerica inc (SCRC) Key Developments

ScripsAmerica Enters Supply Agreement with RapiMed(R) Manufacturer

ScripsAmerica Inc. announced that the company has signed a 2-year manufacturing supply agreement with the manufacturer of its RapiMed(R) children's pain reliever and fever reducer. The recently signed agreement formalizes the working relationship between ScripsAmerica and RapiMed(R)'s manufacturer. The two companies have been working together and just completed ScripsAmerica's first order ticketed for Hong Kong in the amount of $200,000.

ScripsAmerica, Inc. Announces Sales Results of Specialty Pharmacy for the Month of May 2014

ScripsAmerica, Inc. announced that its managed specialty pharmacy reported $1.6 million in prescription sales during the month of May. Main Avenue Pharmacy's $1.6 million in monthly revenue for May represents a 67% increase over April's revenue and 224% increase over March's revenue. ScripsAmerica fully manages the operations of the specialty pharmacy, which focuses on compounding topical creams. May's sales have significantly increased Main Avenue Pharmacy's annual run rate to $19.2 million.

ScripsAmerica, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2014

ScripsAmerica, Inc. announced earnings results for the first quarter ended March 31, 2014. For the period, the company reported $5,097,000 in revenue compared to $2,256,000 in the first quarter of 2013, marking a 126% increase in quarterly revenue year over year. Revenue from operations was $823,859, marking an increase of 187% over the same period in 2013 when it was reported at $287,374. Gross profit was $598,000 compared to a loss of $11,000 for the first quarter of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCRC:US $0.14 USD +0.002

SCRC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,686 INR -14.50
Glenmark Pharmaceuticals Ltd 539.65 INR +2.30
Henry Schein Inc $118.65 USD +0.08
Jubilant Life Sciences Ltd 192.00 INR -1.30
Ranbaxy Laboratories Ltd 550.85 INR -5.30
View Industry Companies

Industry Analysis


Industry Average

Valuation SCRC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCRIPSAMERICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at